BAM15

Mitochondrial uncouplers turn fuel into heat instead of ATP. The classic one, 2,4-dinitrophenol (DNP), is still sold online as a slimming aid despite 62 published deaths [3]. DNP and the lab uncoupler FCCP also act on membranes other than the mitochondrial one. BAM15 was identified in 2014 as an uncoupler that does not depolarise the plasma membrane [1].

Its obesity results are consistent across labs. In diet-induced obese mice it was orally bioavailable, increased nutrient oxidation and reduced body fat. It did not change food intake, lean mass, body temperature, or blood markers of toxicity [2]. A second group found treated mice resisted weight gain, with better glucose control independent of the weight loss [4]. In sarcopenic obese mice it cut body weight while increasing muscle mass and strength [5]. A 2025 comparison of 15 structurally unrelated uncouplers found BAM15 had the best overall effect on body weight, glucose control and liver fat in diabetic db/db mice [6]. Outside obesity, it reduced deaths and kidney injury in a mouse model of sepsis, even when given 12 hours after onset [7].

BAM15 is a lipophilic weak acid. It carries protons into the mitochondrial matrix through a route that bypasses ATP synthase, so nutrient oxidation is uncoupled from ATP production. Respiration rises and reactive oxygen species fall [1]. The energy stress this creates activates AMPK. In liver that improved lipid handling through mitophagy [8], and in muscle it enhanced mitochondrial quality control [5].

In db/db mice, high-dose BAM15 lowered body weight about as much as calorie restriction, but controlled glucose better. It normalised fasting glucose and glucose tolerance and lowered glucagon [9].

There is no human safety data. The central worry with any uncoupler is dose: burning fuel as heat has no built-in ceiling. DNP toxicity shows up as overheating, a racing heart, sweating and rapid breathing, and can end in death [3]. BAM15 has a much wider tolerated range than most uncouplers in cells [6]. In mice it did not raise body temperature or disturb toxicity markers at effective doses [2]. A 2023 review calls the safety profile encouraging, but that is preclinical [10].

Not all of the 15 uncouplers compared in 2025 behaved alike. Eleven impaired maximal mitochondrial capacity, which is a reminder that "uncoupler" is not one safety profile [6].

No human interaction data. In mice it has been combined with the thyroid-receptor-β agonist MGL-3196 (resmetirom). The pair worked better on fatty liver than either alone, with BAM15 driving the body-fat effect [11].